5 matches for your search in the start-up spotlight
rssFirst successful simultaneous 10-target multiplex-screening
09-Jan-2025
QUANTRO Therapeutics, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for ...
28-Oct-2024
QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company is entering into a strategic research collaboration with the group of Dr. Johannes Zuber, a world-leading expert in functional genetics and one ...
Austrian Research Promotion Agency FFG awards funding to QUANTRO to accelerate the next development phase of the company's proprietary research platform
08-Aug-2024
QUANTRO Therapeutics GmbH, a pioneer in the development of novel transcription factor-targeted cancer therapies, announced that the company has received an 18-month research grant from the Austrian Research Promotion Agency (FFG). This will support a EUR 1.7 million research project to scale up ...
06-Jun-2024
QUANTRO Therapeutics, aSpin-out from the research institutes IMBA and IMP in Vienna, announced that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim. In successfully applying QUANTRO’s proprietary QUANTROseq® Transcriptional Fingerprint technology, all ...
Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets
22-Jul-2020
Evotec SE announced that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH, a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing ...